Objective To analyze the clinical efficacy of modified electroconvulsive therapy (MECT) combined with ziprasidone in female patients with refractory schizophrenia. Methods 74 female patients with refractory schizophrenia in our hospital from February 2016 to January 2017 were collected, and were randomly divided into two groups according to the SAS software package, 37 cases in each group. The drug group was treated with ziprasidone, and the combined treatment group was treated with MECT combined with ziprasidone. The clinical efficacy and treatment safety of the two groups were statistically analyzed. Results After 1 week of treatment, the PANSS psychopathology score, positive symptom score, and total PANSS score of the drug group and the combined treatment group were significantly decreased, with statistically significant differences (P<0.05);at the end of the third and fifth week after the treatment, PANSS psychopathology score, positive symptom score, and total PANSS score in the combined treatment group were better than those in the drug group, with statistically significant differences (P<0.05). There was no significant fluctuation of WMS score in the drug group; the WMS score of the combined treatment group was significantly fluctuated at the end of the first week after the treatment, and the WMS score gradually recovered with the prolongation of the treatment time. There were no statistically significant differences in TESS score and SAS score at the end of the first, third, and fifth week after the treatment in the drug group and the combined treatment group (P>0.05). The incidence of adverse reactions during the treatment in the drug group was 29.73％, and that in the combined treatment group was 37.84％, without statistically significant difference (P>0.05). Conclusion Modified electroconvulsive therapy combined with ziprasidone in the treatment of female patients with refractory schizophrenia can get a better effect, and will not increase the adverse reactions.%目的 对女性难治性精神分裂症患者实施无抽搐电休克联合齐拉西酮治疗,并对临床疗效进行分析.方法 收集本院2016年2月至2017年1月收治的74例女性难治性精神分裂症患者的临床资料,按照SAS软件包分层随机法分为药物组和联合组,每组37例,药物组给予齐拉西酮治疗,联合组给予无抽搐电休克联合齐拉西酮治疗.对两组患者的临床治疗效果与治疗安全性进行统计学分析比较.结果 经过1周治疗后,药物组与联合组的阳性与阴性症状量表(PANSS)精神病理评分、阳性症状评分以及PANSS总分均得到显著降低,各指标比较差异均有统计学意义(均P<0.05);治疗进行到第3周末与第5周末时,联合组患者PANSS精神病理评分、阳性症状评分以及PANSS总分降低要优于药物组患者,各指标比较差异均有统计学意义(均P<0.05).药物组治疗期间WMS评分无明显波动,联合组治疗第1周末时WMS评分有较大波动,后期治疗时间的推移,WMS评分渐渐恢复.药物组与联合组治疗第1周、3周、5周末时TESS评分、SAS评分均无明显变化,组间比较差异均无统计学意义(均P>0.05).药物组治疗期间不良反应发生率为29.73％,联合组不良反应发生率为37.84％,两组比较差异无统计学意义(P>0.05).结论 女性难治性精神分裂症患者采用无抽搐电休克联合齐拉西酮治疗,可获得更好的疗效,且不会增加不良反应.
展开▼
